Abbott Laboratories Big Money Sentiment Improved in 2017 Q4 touching 0.91

May 16, 2018 - By Elizabeth Jones

Abbott Laboratories (NYSE:ABT) Corporate Logo

Abbott Laboratories’s Sentiment

“Big money sentiment for Abbott Laboratories (NYSE:ABT) in Q4 2017 increased to 0.91, revealed SEC filings. That’s up 0.04, from 2017Q3’s 0.87. 553 institutional investors started new and increased holdings, while 610 sold and decreased stakes in Abbott Laboratories so the sentiment has improved. These funds own 1.22 billion shares, that’s up from 1.21 billion shares in 2017Q3. Funds holding Abbott Laboratories in top 10 decreased from 59 to 58 for a decrease of 1. In total 52 funds closed positions, 558 reduced and 430 increased. Also 123 funds bought new Abbott Laboratories stakes.

Biggest Abbott Laboratories Investors

Sector Gamma As owns 1.08 million shares in Abbott Laboratories as of Q4 2017. As of Q4 2017, 161,230 shares of Abbott Laboratories are owned by Brandywine Trust Co. Poplar Forest Capital Llc reported 1.21 million shares. The Vermont-based fund Prentiss Smith & Co Inc have invested about 5.37% of the institutional investor’s stock portfolio in Abbott Laboratories. The Delaware-based fund Green Valley Investors Llc looks positive on Abbott Laboratories, owning 1.96 million shares.

Abbott Laboratories manufactures and sells health care products worldwide.The firm is worth $106.60 billion. The companyÂ’s Established Pharmaceutical Products segment offers branded generic pharmaceuticals to treat pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptoms; gynecological disorders; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraines; anti-infective clarithromycin; cardiovascular and metabolic products; and influenza vaccines, as well as to regulate physiological rhythm of the colon.The P/E ratio is 226.04. The Company’s Diagnostic Products segment provides immunoassay and clinical chemistry systems; assays used to screen and/or diagnosis cancer, cardiac, drugs of abuse, fertility, infectious diseases, and therapeutic drug monitoring; hematology systems and reagents; diagnostic systems and cartridges; instruments to automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detects and measures infectious agents; genomic tests; informatics and automation solutions; and a suite of informatics tools and professional services.

The stock increased 0.44% or $0.265 during the last trading session, reaching $60.805.Abbott Laboratories has volume of 2.26M shares. Since May 16, 2017 ABT has risen 34.85% and is uptrending. ABT outperformed by 23.30% the S&P500.

Earnings report for Abbott Laboratories (NYSE:ABT) is expected on July, 19., Zacks reports. Analysts forecast $0.71 earnings per share. That’s $0.09 up or 14.52 % from 2017’s earnings of $0.62. This could be $1.24B profit for ABT assuming the current $0.71 earnings per share will become reality. Wall Street sees 20.34 % EPS growth as of July, 19.

The New Jersey-based Peapack Gladstone Fincl has invested 0.31% in Abbott Laboratories (NYSE:ABT). Lenox Wealth Advsr, New York-based fund reported 60 shs. Tru Communications Of Oklahoma reported 13,637 shs. Earnest Prns Ltd Co holds 859 shs or 0% of its capital. Grisanti Capital Mngmt reported 1,200 shs. Loomis Sayles & L P owns 538,926 shs for 0.06% of their capital. Legal And General Public Llc holds 0.35% or 8.57 million shs. Marco Mngmt Lc has 1.08% invested in Abbott Laboratories (NYSE:ABT) for 124,600 shs. Boston Partners, a Massachusetts-based fund reported 2.32M shs. Mycio Wealth Ptnrs Ltd Llc stated it has 0.06% in Abbott Laboratories (NYSE:ABT). Whittier Of Nevada holds 0.77% or 157,771 shs in its capital. Main Street Research Ltd accumulated 0.05% or 5,404 shs. Meristem Ltd Liability Partnership owns 11,236 shs. Meyer Handelman reported 100,785 shs or 0.28% of all its holdings. Point72 Asset Management L P reported 0.44% in Abbott Laboratories (NYSE:ABT).

Abbott Laboratories registered $23.69 million net activity with 1 insider buy and 20 insider sales since December 14, 2017. On Wednesday, February 28 the insider MANNING JOSEPH J sold $84,344. $183,579 worth of stock was sold by Watkin Jared on Wednesday, March 7. On Friday, May 4 2,150 shs were sold by Bracken Sharon J, worth $125,909. $1.73M worth of stock was sold by Blaser Brian J on Wednesday, January 31. The insider Fussell Stephen R sold $667,804. Ford Robert B sold $2.69M worth of stock or 42,665 shs.

Abbott Laboratories (NYSE:ABT) Ratings Coverage

In total 14 analysts cover Abbott Laboratories (NYSE:ABT). “Buy” rating has 12, “Sell” are 0, while 2 are “Hold”. (NYSE:ABT) has 86% bullish analysts. 20 are the (NYSE:ABT)’s ratings reports on 16 May 2018 according to StockzIntelligence Inc. On Wednesday, January 24 the firm earned “Buy” rating by Stifel Nicolaus. On Tuesday, December 12 BMO Capital Markets upgraded Abbott Laboratories (NYSE:ABT) to “Outperform” rating. On Thursday, January 25 William Blair upgraded Abbott Laboratories (NYSE:ABT) to “Buy” rating. On Thursday, January 25 the company was maintained by Morgan Stanley. On Tuesday, April 24 Citigroup maintained Abbott Laboratories (NYSE:ABT) rating. Citigroup has “Neutral” rating and $65 target. On Wednesday, January 24 the firm has “Buy” rating given by RBC Capital Markets. In Thursday, January 25 report Barclays Capital maintained the stock with “Overweight” rating. The stock rating was maintained by Wells Fargo with “Outperform” on Thursday, January 25. On Tuesday, January 2 the firm has “Overweight” rating given by Morgan Stanley. In Wednesday, April 18 report Jefferies maintained it with “Buy” rating and $6800 target.

Abbott Laboratories (NYSE:ABT) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: